Bristol-Myers
Squibb Company (NYSE:BMY) today announced that Murdo Gordon,
executive vice president and chief commercial officer, is leaving the
company, effective August 3, 2018, to pursue another opportunity.
"On behalf of the company, I want to thank Murdo for his leadership and
the important contributions he’s made in his many years with
Bristol-Myers Squibb,” said Giovanni Caforio, chairman and chief
executive officer, Bristol-Myers Squibb. “Murdo helped build a highly
performing commercial organization and developed a strong bench of
talent, contributing to our competitive position in the market and our
success in delivering innovative medicines to patients.”
The announcement of a new chief commercial officer will be the subject
of a separate communication at a later date.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information about
Bristol-Myers Squibb, visit us at BMS.com
or follow us on LinkedIn,
Twitter,
YouTube
and Facebook.
Bristol-Myers Squibb Media: Laura Hortas, 609-252-4587 laura.hortas@bms.com or Investors: Tim Power, 609-252-7509 timothy.power@bms.com